GNPX - Genprex's begins patient enrollment in Phase 1/2 trial testing lung cancer therapy

Genprex (NASDAQ:GNPX) said it was opening patient enrollment for Phase 1/2 trial testing its lead drug candidate, Reqorsa in combination with Merck's Keytruda in patients with late-stage non-small cell lung cancer (NSCLC). The trial , dubbed Acclaim-2, will test the combination therapy in patients with late-stage NSCLC, whose disease progressed after treatment with Keytruda. Genprex received U.S. Food and Drug Administration’s Fast Track Designation for treatment of the Acclaim-1 patient population in 2021. The company said it expects to complete the Phase 1 portion of Acclaim-2 by the end of Q1 2023. Preclinical data showed that Reqorsa combined with Keytruda was more effective than Keytruda alone in increasing the survival of mice with a humanized immune system that had metastatic lung cancer. The Company expects the Phase 1 portion of the trial to enroll up to 30 patients, while the Phase 2 portion of the study is expected to enroll about 126 patients. GNPX shares rose 1.5%.

For further details see:

Genprex's begins patient enrollment in Phase 1/2 trial testing lung cancer therapy